What topics does this cannabis study cover?

This study covers research on: Endocannabinoid.

Where was this research published?

Published in Journal of pharmaceutical analysis on January 5, 2026.

Better endocannabinoid testing could improve liver disease detection

Q: What did this Review find?

The review identifies **new analytical methods** as essential for accurately measuring low-abundance *endocannabinoids* and eCB-like substances.

Advanced analytical approaches for endocannabinoids and endocannabinoid-like substances: Applications in liver disease research.

Journal of pharmaceutical analysis • January 5, 2026 • Review • Highly Relevant

🤖

AI Summary

This review examines recent advances in measuring endocannabinoids (eCBs) and related lipid messengers, which are present in very small amounts in biological samples. It evaluates newer approaches to sample preparation and analytical testing published from 2017 to 2024, outlining the strengths and limitations of these methods. The goal is more accurate measurement of compounds that interact mainly with the cannabinoid receptors CB1R and CB2R.

The liver is a major site of endocannabinoid-system activity, and disruptions in eCB levels have been linked with various liver diseases and changes in liver lipid metabolism. The review concludes that eCBs and eCB-like substances could become useful diagnostic biomarkers, although the abstract does not report clinical performance data or specific patient outcomes. For cannabis research, the findings reinforce that the body’s own cannabinoid signaling system may be important in liver health, but they do not directly establish benefits or risks from consuming THC or CBD.

💡 Key Findings

The review identifies new analytical methods as essential for accurately measuring low-abundance endocannabinoids and eCB-like substances.

Good

70%

Dysregulated endocannabinoid levels are associated with various liver diseases and may influence liver lipid metabolism.

Good

70%

eCBs and eCB-like substances show potential as diagnostic biomarkers, but the abstract provides no quantitative clinical validation.

Good

60%

The findings concern the body’s endogenous cannabinoid system and do not directly demonstrate effects of THC or CBD use.

High

90%

📄 Original Abstract

Endocannabinoids (eCBs) and eCB-like substances are lipid mediators that play vital roles in regulating diverse physiological and pathological processes. These effects are predominantly mediated through interactions with cannabinoid receptors (CBRs), particularly CB1R and CB2R. Due to their typically low abundance in biological samples, the development of precise and efficient analytical methods is essential for accurate quantification of eCBs. The liver serves as a critical site of eCB activity, where dysregulation of eCB levels has been associated with various liver diseases. This review focuses on recent advancements in sample preparation and analytical techniques for eCBs and eCB-like substances from 2017 to 2024, providing a comprehensive evaluation of their strengths and limitations. Additionally, the roles of eCBs in liver lipid metabolism and their involvement in pathological processes are explored in detail. eCBs and eCB-like substances hold promise as diagnostic biomarkers, offering significant potential for applications in both basic research and clinical practice.

Paper Type

📚 Review

Publication

Journal: Journal of pharmaceutical analysis
Published: January 5, 2026
PMID: 42604040
DOI: 10.1016/j.jpha.2026.101546

Authors (4)

Jun-Yi Zhou The State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, 999078, China.
Yan-Qing Chen The State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, 999078, China.
Hai-Yu Zhao Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Jian-Bo Wan The State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, 999078, China.